Nanox Imaging Ltd. (NASDAQ: NNOX) has taken a significant step toward expanding the reach of its AI-driven diagnostic tools in the United Kingdom. The company announced that its subsidiary, Nanox AI Ltd., has entered into a sales reseller agreement with Vertec Scientific Ltd., granting Vertec an exclusive license to market and resell Nanox.AI's bone solution, HealthOST, across the UK. The agreement, which includes minimum annual license commitments, is set for an initial three-year term.
HealthOST is an FDA-cleared and UKCA/CE-marked AI software solution that analyzes routine CT scans to assist clinicians in evaluating musculoskeletal diseases of the spine, particularly osteoporosis. This technology is designed to identify vertebral fragility fractures, a common yet often undetected indicator of osteoporosis, during scans performed for other medical reasons. By leveraging existing imaging data, HealthOST enables opportunistic screening without additional radiation exposure or patient visits, potentially improving early detection and management of a condition that affects millions worldwide.
The importance of this agreement is underscored by a recent recommendation from the National Institute for Health and Care Excellence (NICE). In November 2025, NICE recommended HealthOST, along with a previous version, HealthVCF, as one of five AI technologies for use in the National Health Service (NHS) to aid in the opportunistic detection of vertebral fragility fractures. This endorsement highlights the clinical and economic value of integrating AI into routine diagnostic pathways, potentially reducing the burden on healthcare systems by preventing fractures through timely intervention.
Vertec Scientific Ltd., a well-established supplier of medical and scientific equipment in the UK, will now play a pivotal role in distributing HealthOST to NHS trusts and private healthcare providers. The exclusive arrangement positions Vertec to leverage its extensive network and expertise to drive adoption, ensuring that this technology reaches clinicians who can benefit most from its capabilities. The partnership aligns with the UK government's strategy to embrace digital health innovations and improve patient outcomes through earlier diagnosis.
For Nanox, this agreement marks another milestone in its mission to transform medical imaging and expand access to preventive care. The company's ecosystem, which includes the Nanox.ARC imaging system, AI-based algorithms, cloud solutions, and teleradiology services, is designed to streamline workflows and support early disease detection. By securing a foothold in the UK market, Nanox is not only advancing its commercial footprint but also contributing to the global effort to combat osteoporosis, a condition that often goes undiagnosed until a fracture occurs.
The NICE recommendation and the subsequent reseller agreement are expected to accelerate the adoption of AI in radiology, setting a precedent for other AI-based diagnostic tools. As healthcare systems worldwide grapple with increasing demands and resource constraints, solutions like HealthOST offer a cost-effective way to enhance diagnostic accuracy and efficiency. The collaboration between Nanox and Vertec is a testament to the growing recognition of AI's potential to revolutionize patient care, particularly in chronic disease management.
With this partnership, Nanox continues to demonstrate its commitment to delivering innovative, clinically validated solutions that address unmet medical needs. The exclusive UK distribution agreement not only expands the reach of HealthOST but also reinforces the company's position as a leader in the integration of AI into mainstream healthcare. As the first year of the agreement unfolds, stakeholders will be watching closely to see how this technology impacts osteoporosis detection rates and patient outcomes in the UK.
